"10.1371_journal.pone.0064449","plos one","2013-05-21T00:00:00Z","Yutaka Takebe; Carrie J Saucedo; Garry Lund; Rie Uenishi; Saiki Hase; Takayo Tsuchiura; Norman Kneteman; Koreen Ramessar; D Lorne J Tyrrell; Masayuki Shirakura; Takaji Wakita; James B McMahon; Barry R O'Keefe","AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan; Molecular Targets Laboratory, SAIC-Frederick, Frederick, Maryland, United States of America; KMT Hepatech, Edmonton, Alberta, Canada; Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America; Virology II, National Institute of Infectious Diseases, Tokyo, Japan","Conceived and designed the experiments: YT TT NK MS TW JBM BRO. Performed the experiments: YT CS GL RU SH KR DLT. Analyzed the data: YT CS GL RU SH TT NK KR DLT MS BRO. Contributed reagents/materials/analysis tools: YT NK MS TW BRO. Wrote the paper: YT GL NK JBM BRO.","The patents for both Griffithsin and Scytovirin are wholly owned by the U.S. Government. Drs. O'Keefe and McMahon are named inventors on patents for both proteins.Norman Kneteman, Garry Lund and Lorne Tyrrell are affiliated to KMT Hepatech which is a contract research organization funded by NIAID for hepatitis C studies with no competing interests. KMT Hepatech has no rights or interests in further developing the antiviral proteins griffithsin and scytovirin for commercial use. Their involvement in this manuscript does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","05","Yutaka Takebe","YT",13,FALSE,7,7,11,5,TRUE,TRUE,FALSE,0,NA,FALSE
